Varga A, et al. - As sustained responses are less likely after second-line and subsequent therapies in patients with ovarian cancer who eventually relapse, researchers evaluated pembrolizumab monotherapy for its safety, tolerability, and antitumor activity in patients with programmed death ligand 1 (PD-L1)–expressing advanced ovarian cancer enrolled in the multicohort, phase Ib KEYNOTE-028 trial. Outcomes revealed modest but durable responses to pembrolizumab in these patients. Pembrolizumab had an acceptable safety profile, with no deaths or treatment-related discontinuations